Treace Medical Concepts (TMCI) Expected to Post Quarterly Earnings on Friday

Key Points

• Treace Medical Concepts is expected to report Q3 2026 results before the market opens on November 6. Analysts forecast a loss of $0.26 per share and revenue of $47.80 million.
• The company exceeded expectations in its latest quarter, reporting a $0.24 per-share loss versus the projected $0.30 loss and revenue of $45.38 million compared with the $44.02 million consensus estimate.
• TMCI shares recently traded at $5.06, up 4.8%, while analysts maintain a consensus “Reduce” rating with an average price target of $5.17. Insiders have purchased nearly 56,000 shares over the past 90 days.

Treace Medical Concepts (NASDAQ:TMCI - Get Free Report) is anticipated to announce its Q3 2026 results before the market opens on Friday, November 6th. Analysts expect Treace Medical Concepts to post earnings of ($0.26) per share and revenue of $47.80 million for the quarter. Individuals may review the information on the company's upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Friday, November 6, 2026 at 8:00 AM ET.

Treace Medical Concepts (NASDAQ:TMCI - Get Free Report) last posted its quarterly earnings results on Friday, August 7th. The company reported ($0.24) EPS for the quarter, topping the consensus estimate of ($0.30) by $0.06. Treace Medical Concepts had a negative net margin of 28.99% and a negative return on equity of 71.37%. The company had revenue of $45.38 million during the quarter, compared to analysts' expectations of $44.02 million. On average, analysts expect Treace Medical Concepts to post ($0.83) EPS for the current fiscal year and ($0.81) EPS for the next fiscal year.

Treace Medical Concepts Trading Up 4.8%

Shares of NASDAQ:TMCI opened at $5.06 on Friday. Treace Medical Concepts has a 52 week low of $1.17 and a 52 week high of $6.65. The company's 50 day moving average is $4.43 and its two-hundred day moving average is $3.24. The company has a current ratio of 2.90, a quick ratio of 1.95 and a debt-to-equity ratio of 0.83. The company has a market cap of $329.10 million, a PE ratio of -5.44 and a beta of 1.48.

Insider Buying and Selling at Treace Medical Concepts

In other news, CEO John Treace purchased 11,000 shares of the company's stock in a transaction that occurred on Monday, August 24th. The shares were purchased at an average price of $4.34 per share, for a total transaction of $47,740.00. Following the purchase, the chief executive officer directly owned 7,404,383 shares of the company's stock, valued at $32,135,022.22. This represents a 0.15% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In the last ninety days, insiders have purchased 55,944 shares of company stock worth $246,841. 23.42% of the stock is currently owned by insiders.

Analysts Set New Price Targets

TMCI has been the subject of several recent analyst reports. Truist Financial boosted their target price on shares of Treace Medical Concepts from $4.00 to $5.00 and gave the stock a "hold" rating in a research note on Monday, August 10th. Weiss Ratings upgraded Treace Medical Concepts from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Monday, August 31st. One equities research analyst has rated the stock with a Buy rating, four have issued a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, Treace Medical Concepts currently has a consensus rating of "Reduce" and an average price target of $5.17.

Treace Medical Concepts Company Profile

Treace Medical Concepts, Inc is a medical device company focused on developing and commercializing products for the surgical treatment of bunion deformities and other conditions affecting the foot and ankle. The company's technologies are designed to address the underlying structural causes of bunions and support more stable correction than traditional surgical approaches.

Treace's primary product is the Lapiplasty 3D Bunion Correction System, which is used by foot and ankle surgeons to correct bunions in three dimensions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.